Nokia chair to step down, AI push supports Q4 profit
Jan 29 (Reuters) – Finland’s Nokia (NOKIA.HE), opens new tab said on Thursday that longtime chair Sari Baldauf…
First-class goods in second-tier cities as luxury goes local in China
Luxury spending in second-tier cities exceeding first-tier Middle-class looks to spend on luxury, save on living costs Gen…
ECB’s Cipollone says geopolitical risks strengthen case for European payments autonomy
MADRID, Jan 28 (Reuters) – Rising geopolitical tensions are firming the case for Europe to develop payment systems…
EU’s answer to Starlink should start up in 2029, commissioner says
BRUSSELS, Jan 27 (Reuters) – The European Union’s multi-orbit array of 290 satellites known as IRIS2 should be…
America Inc’s productivity boom may be going global
ORLANDO, Florida, Jan 26 (Reuters) – The rumblings of a productivity boom are reverberating through the U.S. economy…
OMV CEO says strict rules on plastic recycling could stifle innovation
Item 1 of 2 OMV CEO Alfred Stern briefs journalists in Vienna, Austria September 22, 2025. REUTERS/Lisa Leutner…
Largest European pension fund ABP cut back US Treasury holdings last year
LONDON, Jan 23 (Reuters) – The value of the U.S. Treasuries held by Dutch pension fund ABP, Europe’s…
Europe commits to wind energy expansion despite Trump criticism, draft shows
Item 1 of 2 An aerial view shows wind turbines at the Saint-Nazaire offshore wind farm, off the…
New map reveals hidden landscape under Antarctica’s ice sheet
Item 1 of 4 An undated handout image of a map illustrating the subglacial landscape of mountain ranges,…
Nigeria grants satellite permits to BeetleSat, Satelio and Amazon’s Kuiper
ABUJA, Jan 16 (Reuters) – Nigeria has issued seven-year satellite permits to Amazon’s (AMZN.O), opens new tab Kuiper…
Italy updates Arctic stance as Greenland tensions escalate
ROME, Jan 16 (Reuters) – The Arctic has become a theatre of intensifying strategic rivalry, an Italian government…
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse…